Associated Papers
Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.
Kong J et al.
Bone Marrow Transplantation, 2023
Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers.
Boot A et al.
Proceedings of the National Academy of Sciences of the United States of America, 2022
35058360 (PubMed )
Supplement: pnas.2114024119.sd08.xlsx › Dataset.S8
Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report.
Huang S et al.
Annals of Translational Medicine, 2022
Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors.
Feng Y et al.
Frontiers in Cell and Developmental Biology, 2021
34805171 (PubMed )
Supplement: Table6.XLS › 49_sample_result
Select a paper to view details